APOB and hyperlipidemia: CM1 alleviated hyperlipidemia by downregulating the plasma level of apolipoprotein B48, modulating the expression of key genes and proteins in liver, small intestine and epididymal fat, and inhibiting preadipocyte differentiation in 3T3-L1 cells by suppressing the key genes involved in lipid droplet formation